Terada T, Ohta T, Nakanuma Y
Department of Pathology (II), Kanazawa University School of Medicine, Japan.
Histopathology. 1996 Oct;29(4):355-61. doi: 10.1111/j.1365-2559.1996.tb01419.x.
A few previous studies have demonstrated the expression or mutations of oncogenes and anti-oncogenes as well as that of oncofetal antigens in intraductal papillary-mucinous neoplasm of the pancreas. In this study, we have investigated the immunohistochemical expression of oncogene (ras and c-erbB-2) and anti-oncogene (p53 and retinoblastoma [Rb]) products and oncofetal antigens (CEA, CA19-9 and DUPAN-2) in nine such tumours of the pancreas. In normal pancreas (5 cases), the Rb gene product and CA19-9 were expressed in all cases, while ras and c-erbB-2 gene products, p53 protein, CEA and DUPAN-2 were not expressed. In intraductal papillary-mucinous tumours (n = 9), ras, c-erbB-2, p53 and Rb gene products were present in 4/9 (44%), 7/9 (78%), 0.9 (0%) and 6/9 (67%) cases, respectively. CEA, CA19-9 and DUPAN-2 were expressed in 8/9 (89%), 9/9 (100%) and 2/9 (22%) cases respectively. In invasive ductal adenocarcinoma of the pancrease (7 cases), ras, c-erbB-2, p53 and Rb gene products were expressed in 3/7 (43%), 6/7 (86%), 2/7 (29%) and 3/& (43%) cases respectively. CEA, CA19-9 and DUPAN-2 were expressed in 7/7 (100%), 7/7 (100%) and 6/7 (86%) cases, respectively. The extent and intensity of the expression of these antigens was greater in invasive ductal adenocarcinomas. These data suggest that activation of ras and c-erbB-2 oncogenes and inactivation of Rb anti-oncogene may contribute to the development and progression of intraductal papillary-mucinous tumours of the pancreas and that there is neo-expression of CEA and DUPAN-2 during the development and progression of these tumours.
先前有一些研究已证实，在胰腺导管内乳头状黏液性肿瘤中存在癌基因和抑癌基因的表达或突变，以及癌胚抗原的表达。在本研究中，我们调查了9例此类胰腺肿瘤中癌基因（ras和c-erbB-2）、抑癌基因（p53和视网膜母细胞瘤[Rb]）产物以及癌胚抗原（CEA、CA19-9和DUPAN-2）的免疫组化表达情况。在正常胰腺（5例）中，所有病例均表达Rb基因产物和CA19-9，而ras和c-erbB-2基因产物、p53蛋白、CEA和DUPAN-2均未表达。在导管内乳头状黏液性肿瘤（n = 9）中，ras、c-erbB-2、p53和Rb基因产物分别在4/9（44%）、7/9（78%）、0/9（0%）和6/9（67%）的病例中出现。CEA、CA19-9和DUPAN-2分别在8/9（89%）、9/9（100%）和2/9（22%）的病例中表达。在胰腺浸润性导管腺癌（7例）中，ras、c-erbB-2、p53和Rb基因产物分别在3/7（43%）、6/7（86%）、2/7（29%）和3/7（43%）的病例中表达。CEA、CA19-9和DUPAN-2分别在7/7（100%）、7/7（100%）和6/7（86%）的病例中表达。这些抗原在浸润性导管腺癌中的表达范围和强度更大。这些数据表明，ras和c-erbB-2癌基因的激活以及Rb抑癌基因的失活可能有助于胰腺导管内乳头状黏液性肿瘤的发生和发展，并且在这些肿瘤的发生和发展过程中存在CEA和DUPAN-2的新表达。
